LINC02086: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

Target Name: LINC02086

NCBI ID: G105371809

LINC02086

Other Name(s): Long intergenic non-protein coding RNA 2086, transcript variant X9 | LINC02086 variant X9 | long intergenic non-protein coding RNA 2086

LINC02086: A Long Intergenic Non-Protein-Coding RNA as a Drug Target or Biomarker

LINC02086 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as having potential drug targets or biomarkers. It is a non-coding RNA molecule that is expressed in a variety of cell types and is involved in the regulation of various cellular processes. In this article, we will provide an overview of LINC02086, its potential drug targets, and its potential as a biomarker.

Overview of LINC02086

LINC02086 is a non-coding RNA molecule that is approximately 210 nucleotides long and has been identified in various studies as having potential drug targets or biomarkers. It is expressed in a variety of cell types, including human cancer cells, and is involved in the regulation of various cellular processes, including cell growth, apoptosis, and transcriptional regulation.

Potential Drug Targets

LINC02086 has been identified as a potential drug target due to its involvement in the regulation of cell apoptosis. It has been shown to be involved in the regulation of cell apoptosis by activating the B-cell lymphoma 1 (Bcl-2) gene. Bcl-2 is a protein that has been shown to promote cell survival and prevent apoptosis. By activating Bcl-2, LINC02086 has been shown to promote the survival of cancer cells, making it a potential drug target.

In addition to its involvement in cell apoptosis, LINC02086 has also been shown to be involved in the regulation of cell cycle progression. It has been shown to be involved in the regulation of the G1/S transition, which is a critical step in the cell cycle and is associated with the entry of the cell into the S phase.

Potential Biomarkers

LINC02086 has also been identified as a potential biomarker for a variety of diseases, including cancer. Its involvement in the regulation of cell apoptosis and cell cycle progression makes it a potential biomarker for cancer, particularly B-cell lymphomas.

In addition to its potential as a drug target or biomarker, LINC02086 has also been shown to have potential therapeutic applications in treating various diseases. For example, it has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

Conclusion

In conclusion, LINC02086 is a long intergenic non-protein-coding RNA that has potential as a drug target or biomarker. Its involvement in the regulation of cell apoptosis and cell cycle progression makes it a potential target for cancer therapies. Additionally, its potential as a biomarker for a variety of diseases makes it an attractive candidate for diagnostic applications. Further research is needed to fully understand the potential of LINC02086 as a drug target or biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 2086

The "LINC02086 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02086 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets